ZA201904652B - Combinations of cabozantinib and atezolizumab to treat cancer - Google Patents

Combinations of cabozantinib and atezolizumab to treat cancer

Info

Publication number
ZA201904652B
ZA201904652B ZA2019/04652A ZA201904652A ZA201904652B ZA 201904652 B ZA201904652 B ZA 201904652B ZA 2019/04652 A ZA2019/04652 A ZA 2019/04652A ZA 201904652 A ZA201904652 A ZA 201904652A ZA 201904652 B ZA201904652 B ZA 201904652B
Authority
ZA
South Africa
Prior art keywords
cabozantinib
atezolizumab
combinations
treat cancer
advanced
Prior art date
Application number
ZA2019/04652A
Other languages
English (en)
Inventor
Gisela Schwab
Christian Scheffold
Colin Hessel
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61569414&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201904652(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of ZA201904652B publication Critical patent/ZA201904652B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ZA2019/04652A 2017-01-20 2019-07-16 Combinations of cabozantinib and atezolizumab to treat cancer ZA201904652B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762448869P 2017-01-20 2017-01-20
US201762458447P 2017-02-13 2017-02-13
PCT/US2018/014523 WO2018136796A1 (en) 2017-01-20 2018-01-19 Combinations of cabozantinib and atezolizumab to treat cancer

Publications (1)

Publication Number Publication Date
ZA201904652B true ZA201904652B (en) 2024-11-27

Family

ID=61569414

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2019/04652A ZA201904652B (en) 2017-01-20 2019-07-16 Combinations of cabozantinib and atezolizumab to treat cancer

Country Status (15)

Country Link
US (2) US11198731B2 (https=)
EP (1) EP3570840B1 (https=)
JP (3) JP7222895B2 (https=)
KR (2) KR102610764B1 (https=)
CN (4) CN117205312A (https=)
AU (2) AU2018210397B2 (https=)
BR (1) BR112019015011A2 (https=)
CA (1) CA3049452A1 (https=)
ES (1) ES3031468T3 (https=)
IL (1) IL268138B (https=)
MA (1) MA47310A (https=)
MX (2) MX389966B (https=)
UA (1) UA126970C2 (https=)
WO (1) WO2018136796A1 (https=)
ZA (1) ZA201904652B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME03376B (me) 2010-05-20 2020-01-20 Array Biopharma Inc Makrociklička jedinjenja kао inhibiтori trk kinaze
EP3174854B1 (en) 2014-07-31 2022-08-24 Exelixis, Inc. Method of preparing fluorine-18 labeled cabozantinib and its analogs
EP3442531A1 (en) 2016-04-15 2019-02-20 Exelixis, Inc. Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
WO2018136661A1 (en) 2017-01-18 2018-07-26 Andrews Steven W SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
US11198731B2 (en) * 2017-01-20 2021-12-14 Exelixis, Inc. Combinations of cabozantinib and atezolizumab to treat cancer
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
EP3740490A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
JP7060694B2 (ja) 2018-01-18 2022-04-26 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物
US11472802B2 (en) 2018-01-18 2022-10-18 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
CN117402114A (zh) 2018-01-26 2024-01-16 埃克塞里艾克西斯公司 用于治疗激酶依赖性病症的化合物
TWI831259B (zh) 2018-06-15 2024-02-01 漢達生技醫藥股份有限公司 包含達沙替尼十二烷基硫酸鹽組合物的膠囊
JP7653352B2 (ja) * 2018-09-05 2025-03-28 エクスプレステック、リミテッド、ライアビリティ、カンパニー 免疫グロブリンａ製剤
CN112996794A (zh) 2018-09-10 2021-06-18 阿雷生物药品公司 作为ret激酶抑制剂的稠合杂环化合物
US12138351B2 (en) * 2020-04-14 2024-11-12 Janssen Biotech, Inc. Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof
IL300151A (en) * 2020-07-31 2023-03-01 Exelixis Inc Combinations for cancer treatment
WO2022040555A2 (en) * 2020-08-21 2022-02-24 Exelixis, Inc. Method of treating cancer
WO2022197900A1 (en) * 2021-03-19 2022-09-22 Merck Sharp & Dohme Llc Methods for treating cancer with anti-ilt3 antibodies
US11620580B2 (en) * 2021-04-01 2023-04-04 Banjo Health Inc. Methods and systems for probabilistic filtering of candidate intervention representations
WO2024163400A1 (en) 2023-01-31 2024-08-08 Handa Oncology, Llc Improved cabozantinib compositions and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210607B1 (en) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
US20080200515A1 (en) 2006-12-29 2008-08-21 Tap Pharmaceutical Products Inc. Solid state forms of enantiopure ilaprazole
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
NZ779754A (en) 2009-01-16 2023-04-28 Exelixis Inc Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
EA030435B1 (ru) 2010-07-16 2018-08-31 Экселиксис, Инк. ТАБЛЕТКА, СОДЕРЖАЩАЯ МОДУЛЯТОР c-MET В ФОРМЕ КРИСТАЛЛИЧЕСКОЙ L-МАЛАТНОЙ СОЛИ (ВАРИАНТЫ), СПОСОБ ЕЕ ПРОИЗВОДСТВА И СПОСОБ ЛЕЧЕНИЯ ОНКОЛОГИЧЕСКОГО ЗАБОЛЕВАНИЯ С ЕЕ ИСПОЛЬЗОВАНИЕМ
WO2014165779A1 (en) * 2013-04-04 2014-10-09 Exelixis, Inc. Drug combinations to treat cancer
BR112016018450A2 (pt) * 2014-02-14 2018-09-18 Exelixis Inc formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, processos de preparo e métodos de uso
EP3442531A1 (en) 2016-04-15 2019-02-20 Exelixis, Inc. Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
CN109475545A (zh) * 2016-04-19 2019-03-15 埃克塞里艾克西斯公司 三阴性乳腺癌治疗方法
US11198731B2 (en) 2017-01-20 2021-12-14 Exelixis, Inc. Combinations of cabozantinib and atezolizumab to treat cancer

Also Published As

Publication number Publication date
JP2022121594A (ja) 2022-08-19
IL268138A (en) 2019-09-26
US20220056138A1 (en) 2022-02-24
AU2018210397A1 (en) 2019-07-25
MX2019008032A (es) 2019-12-16
CN117771363A (zh) 2024-03-29
ES3031468T3 (en) 2025-07-09
KR20190107103A (ko) 2019-09-18
US20190352403A1 (en) 2019-11-21
MX2022001718A (es) 2022-03-11
WO2018136796A1 (en) 2018-07-26
MA47310A (fr) 2019-11-27
EP3570840B1 (en) 2025-03-19
KR102610764B1 (ko) 2023-12-07
AU2018210397B2 (en) 2024-02-29
NZ755494A (en) 2025-06-27
BR112019015011A2 (pt) 2020-04-28
CN117205313A (zh) 2023-12-12
CA3049452A1 (en) 2018-07-26
UA126970C2 (uk) 2023-03-01
JP7222895B2 (ja) 2023-02-15
EP3570840A1 (en) 2019-11-27
IL268138B (en) 2022-08-01
MX389966B (es) 2025-03-20
CN117205312A (zh) 2023-12-12
AU2024203472A1 (en) 2024-06-13
JP2020514311A (ja) 2020-05-21
CN110352057A (zh) 2019-10-18
KR20230169458A (ko) 2023-12-15
US11198731B2 (en) 2021-12-14
JP2024019720A (ja) 2024-02-09

Similar Documents

Publication Publication Date Title
ZA201904652B (en) Combinations of cabozantinib and atezolizumab to treat cancer
PH12019502875A1 (en) Antibody molecules to cd73 and uses thereof
MX392368B (es) Composiciones y metodos para el tratamiento del cancer
PH12017501999A1 (en) K-ras modulators
MX2021000710A (es) Composiciones que comprenden cepas bacterianas.
AU2014358850A8 (en) Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer
AU2018265888A1 (en) Use of anti-B7H3 antibodies for treating cancer in the central nervous system
EP4691562A3 (en) Anti-pd-l1 combinations for treating tumors
ZA201905902B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
MX375221B (es) Composiciones que comprenden anticuerpos anti-molécula de adhesión celular relacionada con antígeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cáncer.
WO2014164704A3 (en) Compounds and compositions for the treatment of cancer
EP3134115A4 (en) Methods and compositions for treating metastatic breast cancer and other cancers in the brain
TW201613647A (en) Compounds and compositions for treating HER2 positive tumors
MX2018008427A (es) Combinaciones anti-cd20 para tratar tumores.
HK1255488A1 (zh) 组合t细胞激活和/或检查点抑制剂治疗癌症的肽和肽模拟物
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
WO2020055643A3 (en) Compounds, compositions and methods for treating or preventing her-driven cancers
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
MX2024003228A (es) Compuestos de union al receptor de la hormona antimulleriana tipo ii (amhrii) para prevenir o tratar canceres de pulmon.
MX2019014298A (es) Formas de dosificacion liquida para tratar el cancer.
EA201990370A1 (ru) Терапия рака, связанная с crebbp
EA201691896A1 (ru) Соединения и способы их применения
PH12017502011A1 (en) Recombinant mycobacterium as an immunotherapeutic agent for the treatment of cancer
EP4541423A3 (en) Dosing regimen of avelumab for the treatment of cancer
MX2019002947A (es) Combinaciones que incluyen abx196 para el tratamiento de cancer.